相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis
Timothy M. Dempsey et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
Systematic review and network meta-analysis of approved medicines for the treatment of idiopathic pulmonary fibrosis
Aristeidis Skandamis et al.
JOURNAL OF DRUG ASSESSMENT (2019)
Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry
Laurie Snyder et al.
RESPIRATORY RESEARCH (2019)
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
Toby M. Maher et al.
RESPIRATORY RESEARCH (2019)
Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study
Vincent Cottin et al.
ERJ OPEN RESEARCH (2018)
The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis
Andreas Guenther et al.
RESPIRATORY RESEARCH (2018)
Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry
Helen E. Jo et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
Poor adherence to chronic obstructive pulmonary disease medications in primary care: Role of age, disease burden and polypharmacy
Davide L. Vetrano et al.
GERIATRICS & GERONTOLOGY INTERNATIONAL (2017)
Idiopathic pulmonary fibrosis
Luca Richeldi et al.
LANCET (2017)
Value of a national administrative database to guide public decisions: From the systeme national d'information interregimes de l'Assurance Maladie (SNIIRAM) to the systeme national des donnees de sante (SNDS) in France
P. Tuppin et al.
REVUE D EPIDEMIOLOGIE ET DE SANTE PUBLIQUE (2017)
French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis-2017 update. Full length version
V. Cottin et al.
REVUE DES MALADIES RESPIRATOIRES (2017)
Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis
Steven D. Nathan et al.
LANCET RESPIRATORY MEDICINE (2017)
Burden of Idiopathic Pulmonary Fibrosis Progression: A 5-Year Longitudinal Follow-Up Study
Vincent Cottin et al.
PLOS ONE (2017)
Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis
Miya O. Paterniti et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2017)
Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis
Brett Ley et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2017)
Treatment of idiopathic pulmonary fibrosis: a network meta-analysis
Bram Rochwerg et al.
BMC MEDICINE (2016)
The Best Use of the Charlson Comorbidity Index With Electronic Health Care Database to Predict Mortality
Aurelie Bannay et al.
MEDICAL CARE (2016)
Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials
Luca Richeldi et al.
RESPIRATORY MEDICINE (2016)
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis An Update of the 2011 Clinical Practice Guideline
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Outcomes After Hospitalization in Idiopathic Pulmonary Fibrosis A Cohort Study
A. Whitney Brown et al.
CHEST (2015)
Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review
Ganesh Raghu et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
All-Cause Mortality Rate in Patients with Idiopathic Pulmonary Fibrosis Implications for the Design and Execution of Clinical Trials
Talmadge E. King et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2014)
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Talmadge E. King et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Selection of Clinically Meaningful Primary Endpoints in Phase 3 Clinical Trials in Idiopathic Pulmonary Fibrosis
Williamson Z. Bradford et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
Idiopathic Pulmonary Fibrosis: Clinically Meaningful Primary Endpoints in Phase 3 Clinical Trials
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2012)
Hot off the breath: Mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good
Athol U. Wells et al.
THORAX (2012)
Clinical Course and Prediction of Survival in Idiopathic Pulmonary Fibrosis
Brett Ley et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Paul W. Noble et al.
LANCET (2011)
Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003
Amy L. Olson et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
分享论文
